What the Project Is
Welcome to the Chiesi Group website. Chiesi is an international biopharmaceutical group focused on research that develops and markets innovative therapeutic solutions. The project is centered on areas such as respiratory health, rare diseases, neonatology, and specialty care. With a B Corp score of 103.7, the Group has made its commitment to society and the environment legally binding in Italy, the United States, France, and Colombia – all while maintaining the heritage of a proud Italian pharmaceutical tradition. This project reflects a dedication to research and development, keeping the spirit of innovation and excellence alive.
Main Benefit
The initiative offers a range of tangible benefits and key figures that underscore its leadership in the pharmaceutical industry:
- 90 years of experience in providing top-tier healthcare solutions.
- Focus areas include respiratory health, rare diseases, and neonatology.
- More than 7,500 collaborators working towards a common goal.
- Headquartered in Parma, Italy, with over 30 commercial subsidiaries worldwide.
- Ambitious goal to achieve Net Zero Greenhouse Gas emissions by 2035.
- Certified as a B Corp since 2019, aligning business success with social and environmental impact.
- A robust research network with the Research Center in Parma collaborating with six major R&D hubs across the globe.
Innovation in Pharmaceutical Solutions
Chiesi’s dedication to innovation is palpable – from its deep roots in Italian tradition to its strides in global biopharmaceutical research. Focused on transforming research into market-ready solutions, Chiesi never shies away from taking measured risks. The company’s projects continuously evolve, and the technical expertise in respiratory, neonatology, and rare diseases fields ensures that the research and development pipeline is always buzzing with new ideas… It is a dynamic environment where cutting-edge science meets practical, life-improving applications.
Commitment to Communities & Environment
At the heart of the project lies a strong commitment to doing good. To fulfill its mission of improving people’s quality of life, the Group acts responsibly not only towards patients but also for the communities in which it operates – and for the environment. This commitment is embedded in every decision made, making sure that each step forward benefits both society and the natural world. The ethos of shared value is evident in practices that support sustainability and community wellbeing, while the company pursues a future with reduced environmental impact.
Global Presence & Collaboration
Chiesi, with its 90 years of expertise, stands as a pillar in the pharmaceutical industry. Headquartered in Parma, Italy, the Group has established a significant global footprint with more than 30 commercial subsidiaries worldwide. The Research Center in Parma collaborates seamlessly with six major R&D hubs in France, the United States, Canada, China, the United Kingdom, and Sweden. This network not only bolsters research and development efforts but also encourages a free flow of ideas and innovation across borders… Such a collaborative spirit ensures that breakthroughs in pharmaceutical practices can reach patients and communities quickly and effectively.
Excellence in Research and Therapeutic Development
Throughout its long history, Chiesi has remained committed to scientific excellence. Its deep involvement in biopharmaceutical research means that every project is nurtured with a blend of tradition and modern science. By leveraging the expertise of researchers and collaborators across leading global hubs, the project delves into the intricacies of respiratory conditions, rare disorders, and specialized care needs. The continual push for improvement and refinement in products and services not only champions the cause of healthcare innovation – it also reinforces the trust placed in a company that values research and development as a cornerstone of its mission.
Project Impact
- SDG 3: Good Health and Well-being – Enhancing patient lives with innovative therapeutic solutions.
- SDG 9: Industry, Innovation, and Infrastructure – Building robust, globally connected R&D hubs that drive medical breakthroughs.
- SDG 13: Climate Action – Aiming for Net Zero Greenhouse Gas emissions by 2035 and reducing environmental impact.
- SDG 17: Partnerships for the Goals – Collaborating with international hubs to foster shared knowledge and expertise.
The Future in Research & Development
The path forward for Chiesi is paved with promise and determination. In a world where the need for innovative solutions in healthcare is ever-growing, the Group remains at the forefront of finding answers to complex medical challenges. By integrating rigorous scientific research with a commitment to improving quality of life, each project undertaken contributes to a future where therapeutic solutions are both advanced and accessible. This focus on research and development not only pushes the boundaries of what is possible but also reinforces the long-standing reputation of the company as a pioneering force in the pharmaceutical industry. Through a blend of Italian passion, modern innovation, and a global perspective, this project continues to shape the future of healthcare, ensuring that high-quality, innovative treatments remain within reach for those who need them most.
